Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2011

View Archived Issues

Recombinant PDGF-BB shows promise in tendinopathy and osteochondral defect repair

Mapatumumab/sorafenib combination is safe in patients with advanced HCC and chronic hepatitis

Researchers induce bone repair via "same day" ex vivo regional gene therapy in rats

New inhibitors claimed of lymphokine-activated killer T-cell-originated protein kinase

CHMP recommends approval of Pravafenix

Photodegradable hydrogels with tunable properties synthesized to improve 2D/3D cell culture

AZD-0530 suppresses migration of biliary cancer cells in vitro

Dutch scientists present new bradykinin B1 receptor antagonists

Galderma discloses novel inhibitors of ADAM 17

Furiex's MuDelta receives FDA fast track status for D-IBS

Angion Biomedica patents new PARP-1 inhibitors

Phase III trial confirms safety of Latuda in schizophrenia

Senesco Tech submits IND to FDA for SNS01-T in multiple myeloma

Korean researchers develop (R)-bicalutamide prodrug

Oxford BioTherapeutics out-licenses antibody to sanofi-aventis

New HCV NS5B inhibitors claimed by Roche

Takeda Bio begins Japanese portion of phase III AMG-386 trial

Enrollment resumed in phase II DCVax-Brain trial in glioblastoma multiforme

GenVec and U.S. NMRC collaborate on vaccine for dengue fever

TPIAO approved in China for idiopathic thrombocytopenic purpura

TRU-016/bendamustine combination enters phase Ib/II trial in CLL

GSK begins phase III trials of GSK-2118436 and GSK-1120212 in melanoma

Amgen to acquire BioVex and its oncolytic vaccine OncoVEX(GM-CSF)

Generex to modify enrollment in phase II AE-37 trial in breast cancer

Photocure reports final follow-up data from phase IIa study of Cevira

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...